There is a vast amount of data regarding specific gene and protein targets, especially in the post genomics era with many well validated targets, and even more "strong candidates". Drug companies have libraries of compounds that could be good inhibitors/enhancers for these new targets but lack an internal program, IP of the target, or a sufficiently large market to initiate risky and expensive drug screens, let alone... more »

There is a need to encourage the development and growth of integrated and multi-disciplinary biomedical research skills needed to utilize emerging technology, infrastructure, and paradigms, including the development of competitive research training strategies that embrace the role of multi-institutional and professional scientific organization research collaboration.

There is a need for better collaboration with industry.

Vascular anomaly research is currently making exciting advances but discovery is hampered by lack of funding and collaborative prospective studies

During recent years, clinical research including well-organized randomized clinical trials in developed countries generated large database and human biological sample banks. These are valuable resources for human disease research. Mechanisms to encourage and facilitate international collaboration for genetic and metabolic research using database and human biological samples from specific human disease population of international... more »

The lack of transparency in Pharma clinical studies and the incomplete knowledge of the effect of genetic profiles and pharmacological factors on drug toxicities are challenges in decreasing drug development costs and increasing drug safety.